Inflammasome and cytokine blocking strategies in autoinflammatory disorders

Clinical Immunology

Volumn 147, Issue 3, 2013, Pages 242-275

  Moll, Monika ^a   Kuemmerle Deschner, Jasmin B ^a  

^a University Children's Hospital Tuebingen   (Germany)

Author keywords

Autoinflammatory disorders; Cytokines; Genetic disorders; IL 1 inhibition; Inflammasome

Indexed keywords

ADALIMUMAB; CANAKINUMAB; COLCHICINE; CRYOPYRIN; CYTOKINE RECEPTOR ANTAGONIST; ETANERCEPT; GEVOKIZUMAB; HLA B27 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INFLIXIMAB; INTERLEUKIN 1; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; TOCILIZUMAB; ANTIRHEUMATIC AGENT; HYBRID PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; NFKB1 PROTEIN, HUMAN;

AA AMYLOIDOSIS; AMYLOIDOSIS; AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; AUTOSOMAL RECESSIVE INHERITANCE; BEHCET DISEASE; BLAU SYNDROME; CHRONIC ATYPICAL NEUTROPHILIC DERMATITIS WITH LIPODYSTROPHY AND ELEVATED TEMPERATURE; CHRONIC OSTEOMYELITIS; CHRONIC RECURRENT MULTIFOCAL OSTEOMYELITIS; CINCA SYNDROME; CYTOKINE PRODUCTION; DEFICIENCY OF THE INTERLEUKIN 1 RECEPTOR ANTAGONIST; DEFICIENCY OF THE INTERLEUKIN 36 RECEPTOR ANTAGONIST; DERMATITIS; ENZYME ACTIVATION; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL MEDITERRANEAN FEVER; GENE MUTATION; GENETIC ASSOCIATION; GOUT; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; INNATE IMMUNITY; JUVENILE RHEUMATOID ARTHRITIS; MAJEED SYNDROME; META ANALYSIS (TOPIC); MUCKLE WELLS SYNDROME; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PAPA SYNDROME; PFAPA SYNDROME; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSEUDOGOUT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHNITZLER SYNDROME; SPONDYLOARTHROPATHY; TEMPERATURE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; DRUG ANTAGONISM; HEREDITARY PERIODIC FEVER; IMMUNOLOGY; METABOLISM;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ENZYME ACTIVATION; HEREDITARY AUTOINFLAMMATORY DISEASES; HUMANS; INFLAMMASOMES; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; NF-KAPPA B P50 SUBUNIT; RECOMBINANT FUSION PROTEINS;

EID: 84882274510     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.04.008     Document Type: Review

References (319)

1. D.L. Kastner, I. Aksentijevich, R. Goldbach-Mansky, Autoinflammatory disease reloaded: a clinical perspective, Cell 140 (2010). 784-790.
2. D. McGonagle, M.F. McDermott, A proposed classification of the immunological diseases, PLoS Med. 3 (2006). e297.
3. H. Park, A.B. Bourla, D.L. Kastner, R.A. Colbert, R.M. Siegel, Lighting the fires within: the cell biology of autoinflammatory diseases, Nat. Rev. Immunol. 12 (2012). 570-580.
4. J.D. Gillmore, L.B. Lovat, M.R. Persey, M.B. Pepys, P.N. Hawkins, Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein, Lancet 358 (2001). 24-29.
5. I. Muscari, F. Iacoponi, L. Cantarini, O.M. Lucherini, G. Simonini, et al., The diagnostic evaluation of patients with potential adult-onset autoinflammatory disorders: Our experience and review of the literature, Autoimmun. Rev. (2012).
6. J.P. Drenth, J.W. van der Meer, Hereditary periodic fever, N. Engl. J. Med. 345 (2001). 1748-1757.
7. M.F. McDermott, I. Aksentijevich, J. Galon, E.M. McDermott, B.W. Ogunkolade, et al., Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes, Cell 97 (1999). 133-144.
8. [1997] Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell 90: 797-807.
9. [1997] A candidate gene for familial Mediterranean fever. Nat Genet 17: 25-31.
10. H.M. Hoffman, J.L. Mueller, D.H. Broide, A.A. Wanderer, R.D. Kolodner, Mutation of a newgene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome, Nat. Genet. 29 (2001). 301-305.
11. J. Feldmann, A.M. Prieur, P. Quartier, P. Berquin, S. Certain, et al., Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes, Am. J. Hum. Genet. 71 (2002). 198-203.
12. I. Aksentijevich, M. Nowak, M. Mallah, J.J. Chae, W.T. Watford, et al., De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases, Arthritis Rheum. 46 (2002). 3340-3348.
13. J.P. Drenth, L. Cuisset, G. Grateau, C. Vasseur, S.D. van de Velde-Visser, et al., Mutations in the gene encodingmevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper-IgD Study Group, Nat. Genet. 22 (1999). 178-181.
14. S.M. Houten, W. Kuis, M. Duran, T.J. de Koning, A. van Royen-Kerkhof, et al., Mutations in MVK, encoding mevalonate kinase, cause hyperimmunoglobulinaemia D and periodic fever syndrome, Nat. Genet. 22 (1999) 175-177.
15. I. Aksentijevich, S.L. Masters, P.J. Ferguson, P. Dancey, J. Frenkel, et al., An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist, N. Engl. J. Med. 360 (2009). 2426-2437.
16. S. Marrakchi, P. Guigue, B.R. Renshaw, A. Puel, X.Y. Pei, et al., Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis, N. Engl. J. Med. 365 (2011). 620-628.
17. C. Henderson, R.Goldbach-Mansky, Monogenic autoinflammatory diseases: new insights into clinical aspects and pathogenesis, Curr. Opin. Rheumatol. 22 (2010) 567-578.
18. V.U. Ozkurede, L. Franchi, Immunology in clinic review series; focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromes, Clin. Exp. Immunol. 167 (2012). 382-390.
19. M. Gattorno, A. Martini, Treatment of autoinflammatory syndromes, Curr. Opin. Pediatr. 22 (2010). 771-778.
20. I. Aksentijevich, D.L. Kastner, Genetics of monogenic autoinflammatory diseases: past successes, future challenges, Nat. Rev. Rheumatol. 7 (2011). 469-478.
21. S.L. Masters, A. Simon, I. Aksentijevich, D.L. Kastner, Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*), Annu. Rev. Immunol. 27 (2009). 621-668.
22. F. Martinon, V. Petrilli, A. Mayor, A. Tardivel, J. Tschopp, Gout-associated uric acid crystals activate the NALP3 inflammasome, Nature 440 (2006) 237-241.
23. C. Janeway, Immunogenicity signals 1,2,3 and 0, Immunol. Today 10 (1989). 283-286.
24. R. Medzhitov, C.A. Janeway Jr., Innate immunity: the virtues of a nonclonal system of recognition, Cell 91 (1997) 295-298.
25. P. Matzinger, Tolerance, danger, and the extended family, Annu. Rev. Immunol. 12 (1994) 991-1045.
26. S.Y. Seong, P. Matzinger, Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses, Nat. Rev. Immunol. 4 (2004) 469-478.
27. G.S. Panayi, V.M. Corrigall, B. Henderson, Stress cytokines: pivotal proteins in immune regulatory networks; Opinion, Curr. Opin. Immunol. 16 (2004) 531-534.
28. P. Scaffidi, T. Misteli, M.E. Bianchi, Release of chromatin protein HMGB1 by necrotic cells triggers inflammation, Nature 418 (2002) 191-195.
29. K.A. Scheibner, M.A. Lutz, S. Boodoo, M.J. Fenton, J.D. Powell, et al., Hyaluronan fragments act as an endogenous danger signal by engaging TLR2, J. Immunol. 177 (2006) 1272-1281.
30. J.M. Boeynaems, D. Communi, Modulation of inflammation by extracellular nucleotides, J. Invest. Dermatol. 126 (2006) 943-944.
31. M.J. Bours, E.L. Swennen, F. Di Virgilio, B.N. Cronstein, P.C. Dagnelie, Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation, Pharmacol. Ther. 112 (2006) 358-404.
32. Y. Shi, J.E. Evans, K.L. Rock, Molecular identification of a danger signal that alerts the immune system to dying cells, Nature 425 (2003) 516-521.
33. A.M. Farkas, T.M. Kilgore, M.T. Lotze, Detecting DNA: getting and begetting cancer, Curr. Opin. Investig. Drugs 8 (2007) 981-986.
34. H. Wittkowski, J.B. Kuemmerle-Deschner, J. Austermann, D. Holzinger, R. Goldbach-Mansky, et al., MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes, Ann. Rheum. Dis. 70 (2011) 2075-2081.
35. D. Holzinger, M. Frosch, A. Kastrup, F.H. Prince, M.H. Otten, et al., The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis, Ann. Rheum. Dis. 71 (2012) 974-980.
36. F. Martinon, K. Burns, J. Tschopp, The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta, Mol. Cell 10 (2002) 417-426.
37. L. Agostini, F.Martinon, K. Burns,M.F.McDermott, P.N. Hawkins, et al., NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder, Immunity 20 (2004) 319-325.
38. F. Martinon, A. Mayor, J. Tschopp, The inflammasomes: guardians of the body, Annu. Rev. Immunol. 27 (2009) 229-265.
39. M. Kovarova, P.R. Hesker, L. Jania, M. Nguyen, J.N. Snouwaert, et al., NLRP1-dependent pyroptosis leads to acute lung injury and morbidity in mice, J. Immunol. 189 (2012) 2006-2016.
40. Y. Zhao, J. Yang, J. Shi, Y.N. Gong, Q. Lu, et al., The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus, Nature 477 (2011) 596-600.
41. V. Hornung, A. Ablasser, M. Charrel-Dennis, F. Bauernfeind, G. Horvath, et al., AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC, Nature 458 (2009) 514-518.
42. V.A. Rathinam, Z. Jiang, S.N. Waggoner, S. Sharma, L.E. Cole, et al., The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses, Nat. Immunol. 11 (2010) 395-402.
43. V. Hornung, F. Bauernfeind, A. Halle, E.O. Samstad, H. Kono, et al., Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization, Nat. Immunol. 9 (2008) 847-856.
44. A. Halle, V. Hornung, G.C. Petzold, C.R. Stewart, B.G. Monks, et al., The NALP3 inflammasome is involved in the innate immune response to amyloid-beta, Nat. Immunol. 9 (2008) 857-865.
45. Y. Jiang, M. Wang, K. Huang, Z. Zhang, N. Shao, et al., Oxidized low-density lipoprotein induces secretion of interleukin-1beta by macrophages via reactive oxygen species-dependent NLRP3 inflammasome activation, Biochem. Biophys. Res. Commun. 425 (2012) 121-126.
46. P. Duewell, H. Kono, K.J. Rayner, C.M. Sirois, G. Vladimer, et al., NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals, Nature 464 (2010) 1357-1361.
47. F.G. Bauernfeind, G. Horvath, A. Stutz, E.S. Alnemri, K. MacDonald, et al., Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression, J. Immunol. 183 (2009) 787-791.
48. L. Franchi, T. Eigenbrod, G. Nunez, Cutting edge: TNF-alpha mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation, J. Immunol. 183 (2009) 792-796.
49. J. Segovia, A. Sabbah, V. Mgbemena, S.Y. Tsai, T.H. Chang, et al., TLR2/MyD88/NF-kappaB pathway, reactive oxygen species, potassium efflux activates NLRP3/ASC inflammasome during respiratory syncytial virus infection, PLoS One 7 (2012) e29695.
50. R. Goldbach-Mansky, D.L. Kastner, Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses, J. Allergy Clin. Immunol. 124 (2009) 1141-1149, quiz 1150-1141.
51. J.F. Balavoine, B. de Rochemonteix, K. Williamson, P. Seckinger, A. Cruchaud, et al., Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s), J. Clin. Invest. 78 (1986) 1120-1124.
52. C.H. Hannum, C.J. Wilcox, W.P. Arend, F.G. Joslin, D.J. Dripps, et al., Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor, Nature 343 (1990) 336-340.
53. T.A. Doherty, S.D. Brydges, H.M. Hoffman, Autoinflammation: translating mechanism to therapy, J. Leukoc. Biol. 90 (2011) 37-47.
54. E.J. van Asseldonk, R. Stienstra, T.B. Koenen, L.A. Joosten, M.G. Netea, et al., Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study, J. Clin. Endocrinol. Metabol. 96 (2011) 2119-2126.
55. A. Rissanen, C.P. Howard, J. Botha, T. Thuren, Effect of anti-IL-1beta antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial, Diabetes Obes. Metab. 14 (2012) 1088-1096.
56. C. Henderson, R. Goldbach-Mansky, Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: finding the right balance in response to danger signals, Clin. Immunol. 135 (2010) 210-222.
57. A. So, T. De Smedt, S. Revaz, J. Tschopp, A pilot study of IL-1 inhibition by anakinra in acute gout, Arthritis Res. Ther. 9 (2007) R28.
58. R. Terkeltaub, J.S. Sundy, H.R. Schumacher, F. Murphy, S. Bookbinder, et al., The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebocontrolled, monosequence crossover, non-randomised, singleblind pilot study, Ann. Rheum. Dis. 68 (2009) 1613-1617.
59. N. Schlesinger, M. De Meulemeester, A. Pikhlak, A.E. Yucel, D. Richard, et al., Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study, Arthritis research & therapy 13 (2011) R53.
60. C.M. Larsen, M. Faulenbach, A. Vaag, A. Volund, J.A. Ehses, et al., Interleukin-1-receptor antagonist in type 2 diabetes mellitus, N. Engl. J. Med. 356 (2007) 1517-1526.
61. C. Botsios, P. Sfriso, A. Furlan, L. Punzi, C.A. Dinarello, Resistant Behcet disease responsive to anakinra, Ann. Intern. Med. 149 (2008) 284-286.
62. L. Cantarini, A. Vitale, M. Borri, M. Galeazzi, R. Franceschini, Successful use of canakinumab in a patient with resistant Behcet's disease, Clin. Exp. Rheumatol. 30 (2012) S115.
63. S. Ugurlu, D. Ucar, E. Seyahi, G. Hatemi, S. Yurdakul, Canakinumab in a patient with juvenile Behcet's syndrome with refractory eye disease, Ann. Rheum. Dis. 71 (2012) 1589-1591.
64. T. Lequerre, P. Quartier, D. Rosellini, F. Alaoui, M. De Bandt, et al., Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France, Ann. Rheum. Dis. 67 (2008) 302-308.
65. N. Ruperto, P. Quartier, N. Wulffraat, P. Woo, A. Ravelli, et al., A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features, Arthritis Rheum. 64 (2012) 557-567.
66. A. Hess, R. Axmann, J. Rech, S. Finzel, C. Heindl, et al., Blockade of TNF-alpha rapidly inhibits pain responses in the central nervous system, Proc. Natl. Acad. Sci. U. S. A. 108 (2011) 3731-3736.
67. P.N. Hawkins, H.J. Lachmann, M.F. McDermott, Interleukin-1-receptor antagonist in the Muckle-Wells syndrome, N. Engl. J. Med. 348 (2003) 2583-2584.
68. R. Goldbach-Mansky, N.J. Dailey, S.W. Canna, A. Gelabert, J. Jones, et al., Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition, N. Engl. J. Med. 355 (2006) 581-592.
69. J.B. Kuemmerle-Deschner, P.N. Tyrrell, I. Koetter, H. Wittkowski, A. Bialkowski, et al., Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome, Arthritis Rheum. 63 (2011) 840-849.
70. C.M. Hedrich, N. Bruck, B. Fiebig, M. Gahr, Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA), Rheumatol. Int. 32 (2012) 3525-3530.
71. U. Meinzer, P. Quartier, J.F. Alexandra, V. Hentgen, F. Retornaz, et al., Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature, Semin. Arthritis Rheum. 41 (2011) 265-271.
72. E.J. Bodar, L.M. Kuijk, J.P. Drenth, J.W. van der Meer, A. Simon, et al., On-demand anakinra treatment is effective in mevalonate kinase deficiency, Ann. Rheum. Dis. 70 (2011) 2155-2158.
73. L. Obici, A. Meini, M. Cattalini, S. Chicca, M. Galliani, et al., Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis, Ann. Rheum. Dis. 70 (2011) 1511-1512.
74. S. Cohen, E. Hurd, J. Cush, M. Schiff, M.E. Weinblatt, et al., Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial, Arthritis Rheum. 46 (2002) 614-624.
75. H.M. Hoffman, Rilonacept for the treatment of cryopyrinassociated periodic syndromes (CAPS), Expert Opin. Biol. Ther. 9 (2009) 519-531.
76. R. Goldbach-Mansky, S.D. Shroff, M. Wilson, C. Snyder, S. Plehn, et al., A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome, Arthritis Rheum. 58 (2008) 2432-2442.
77. H.M. Hoffman, M.L. Throne, N.J. Amar, M. Sebai, A.J. Kivitz, et al., Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies, Arthritis Rheum. 58 (2008) 2443-2452.
78. P. Hashkes, D. Lovell, E. Giannini, B. Huang, D. Kastner, Rilonacept (IL-1trap) for treatment of colchicine resistant familial Mediterranean fever: a randomized, multicenter double-blinded, alternating treatment trial, Clin. Exp. Rheumatol. 26 (2008) 193.
79. D. Lovell, E. Giannini, Y. Kimura, et al., Preliminary evidence for bioactivity of IL-1 trap (rilonacept), a long acting IL-1 inhibitor. in systemic juvenile idiopathic arthritis, Ann. Rheum. Dis. 65 (2006) 693.
80. K. Krause, K. Weller, R. Stefaniak, H. Wittkowski, S. Altrichter, et al., Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study, Allergy 67 (2012) 943-950.
81. H.J. Lachmann, I. Kone-Paut, J.B. Kuemmerle-Deschner, K.S. Leslie, E. Hachulla, et al., Use of canakinumab in the cryopyrin-associated periodic syndrome, N. Engl. J. Med. 360 (2009) 2416-2425.
82. A. So, M. De Meulemeester, A. Pikhlak, A.E. Yucel, D. Richard, et al., Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study, Arthritis Rheum. 62 (2010) 3064-3076.
83. N. Schlesinger, E. Mysler, H.Y. Lin, M. De Meulemeester, J. Rovensky, et al., Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study, Ann. Rheum. Dis. 70 (2011) 1264-1271.
84. P.M. Ridker, T. Thuren, A. Zalewski, P. Libby, Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), Am. Heart J. 162 (2011) 597-605.
85. C. Galeotti, U. Meinzer, P. Quartier, L. Rossi-Semerano, B. Bader-Meunier, et al., Efficacy of interleukin-1-targeting drugs in mevalonate kinase deficiency, Rheumatology 51 (2012) 1855-1859.
86. M.G. Brizi, M. Galeazzi, O.M. Lucherini, L. Cantarini, R. Cimaz, Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canakinumab, Ann. Intern. Med. 156 (2012) 907-908.
87. S. Vanderschueren, D. Knockaert, Canakinumab in Schnitzler syndrome, Semin. Arthritis Rheum. 42 (2013) 413-416.
88. A.M. Owyang, H. Issafras, J. Corbin, K. Ahluwalia, P. Larsen, et al., XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1beta-mediated diseases, MAbs 3 (2011) 49-60.
89. A. Gul, I. Tugal-Tutkun, C.A. Dinarello, L. Reznikov, B.A. Esen, et al., Interleukin-1beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study, Ann. Rheum. Dis. 71 (2012) 563-566.
90. N. Tanaka, K. Izawa, M.K. Saito, M. Sakuma, K. Oshima, et al., High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study, Arthritis Rheum. 63 (2011) 3625-3632.
91. N. Ter Haar, H. Lachmann, S. Ozen, P. Woo, Y. Uziel, et al., Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review, Ann. Rheum. Dis. 72 (2013) 678-685.
92. H.M. Hoffman, A.A. Wanderer, D.H. Broide, Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever, J. Allergy Clin. Immunol. 108 (2001) 615-620.
93. B. Stych, D. Dobrovolny, Familial cold auto-inflammatory syndrome (FCAS): characterization of symptomatology and impact on patients' lives, Curr. Med. Res. Opin. 24 (2008) 1577-1582.
94. I. Kone-Paut, H.J. Lachmann, J.B. Kuemmerle-Deschner, E. Hachulla, K.S. Leslie, et al., Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study, Arthritis Res. Ther. 13 (2011) R202.
95. H.M. Hoffman, S. Rosengren, D.L. Boyle, J.Y. Cho, J. Nayar, et al., Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist, Lancet 364 (2004) 1779-1785.
96. J.B. Ross, L.A. Finlayson, P.J. Klotz, R.G. Langley, R. Gaudet, et al., Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up, J. Cutan. Med. Surg. 12 (2008) 8-16.
97. J.B. Kuemmerle-Deschner, E. Hachulla, R. Cartwright, P.N. Hawkins, T.A. Tran, et al., Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrinassociated periodic syndrome across different severity phenotypes, Ann. Rheum. Dis. 70 (2011) 2095-2102.
98. A. Koitschev, K. Gramlich, S. Hansmann, S. Benseler, S.K. Plontke, et al., Progressive familial hearing loss in Muckle-Wells syndrome, Acta Oto-laryngol. 132 (2012) 756-762.
99. H.J. Lachmann, H.J. Goodman, J.A. Gilbertson, J.R. Gallimore, C.A. Sabin, et al., Natural history and outcome in systemic AA amyloidosis, N. Engl. J. Med. 356 (2007) 2361-2371.
100. R.L. Glaser, R. Goldbach-Mansky, The spectrum of monogenic autoinflammatory syndromes: understanding disease mechanisms and use of targeted therapies, Curr. Allergy Asthma Rep. 8 (2008) 288-298.
101. T. Mirault, D. Launay, L. Cuisset, E. Hachulla, M. Lambert, et al., Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra, Arthritis Rheum. 54 (2006) 1697-1700.
102. B. Neven, I. Marvillet, C. Terrada, A. Ferster, N. Boddaert, et al., Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome, Arthritis Rheum. 62 (2010) 258-267.
103. C.H. Sibley, N. Plass, J. Snow, E.A. Wiggs, C.C. Brewer, et al., Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes, Arthritis Rheum. 64 (2012) 2375-2386.
104. J.L. Kitley, H.J. Lachmann, A. Pinto, L. Ginsberg, Neurologic manifestations of the cryopyrin-associated periodic syndrome, Neurology 74 (2010) 1267-1270.
105. L. Lepore, G. Paloni, R. Caorsi, M. Alessio, D. Rigante, et al., Follow-up and quality of life of patients with cryopyrinassociated periodic syndromes treated with Anakinra, J. Pediatr. 157 (310-315) (2010) e311.
106. K.S. Leslie, H.J. Lachmann, E. Bruning, J.A. McGrath, A. Bybee, et al., Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations, Arch. Dermatol. 142 (2006) 1591-1597.
107. H.M. Hoffman, A. Simon, Recurrent febrile syndromes: what a rheumatologist needs to know, Nat. Rev. Rheumatol. 5 (2009) 249-256.
108. J.J. Chae, Y.H. Cho, G.S. Lee, J. Cheng, P.P. Liu, et al., Gain-of-function Pyrin mutations induce NLRP3 proteinindependent interleukin-1beta activation and severe autoinflammation in mice, Immunity 34 (2011) 755-768.
109. J.J. Chae, G. Wood, S.L. Masters, K. Richard, G. Park, et al., The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production, Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 9982-9987.
110. C. Fonnesu, C. Cerquaglia, M. Giovinale, V. Curigliano, E. Verrecchia, et al., Familial Mediterranean Fever: a review for clinical management, Joint Bone Spine 76 (2009) 227-233.
111. T. Kallinich, D. Haffner, T. Niehues, K. Huss, E. Lainka, et al., Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement, Pediatrics 119 (2007) e474-e483.
112. R. Roldan, A.M. Ruiz, M.D. Miranda, E. Collantes, Anakinra: new therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine, Joint Bone Spine 75 (2008) 504-505.
113. L. Calligaris, F. Marchetti, A. Tommasini, A. Ventura, The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever, Eur. J. Pediatr. 167 (2008) 695-696.
114. C. Moser, G. Pohl, I. Haslinger, S. Knapp, D. Rowczenio, et al., Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation, Nephrol. Dial. Transplant. 24 (2009) 676-678.
115. R. Gattringer, H. Lagler, K.B. Gattringer, S. Knapp, H. Burgmann, et al., Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: effective but risky, Eur. J. Clin. Invest. 37 (2007) 912-914.
116. L.M. Kuijk, A.M. Govers, J. Frenkel, W.J. Hofhuis, Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra, Ann. Rheum. Dis. 66 (2007) 1545-1546.
117. I. Mitroulis, V.P. Papadopoulos, T. Konstantinidis, K. Ritis, Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient, Neth. J. Med. 66 (2008) 489-491.
118. S. Hennig, K. Bayegan, M. Uffmann, F. Thalhammer, S. Winkler, Pneumonia in a patient with familial Mediterranean fever successfully treated with anakinra-case report and review, Rheumatol. Int. 32 (2012) 1801-1804.
119. I. Ben-Zvi, A. Livneh, The Israeli Annual FMF, Amyloidosis and Other Autoinflammatory Diseases Meeting (July 2011): a bridge spanning these entities, The Israel Medical Association journal: IMAJ 14 (2012) 219-220.
120. I. Mitroulis, P. Skendros, A. Oikonomou, A.G. Tzioufas, K. Ritis, The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis, Ann. Rheum. Dis. 70 (2011) 1347-1348.
121. S. Daysal, G. Akcil, B. Goker, S. Haznedaroglu, N. Ercan, et al., Infliximab therapy in a patient with familial Mediterranean fever and chronic hip arthritis, Arthritis Rheum. 53 (2005) 146-147.
122. E. Seyahi, H. Ozdogan, S. Celik, S. Ugurlu, H. Yazici, Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents, Clin. Exp. Rheumatol. 24 (2006) S99-S103.
123. S. Ozgocmen, L. Ozcakar, O. Ardicoglu, E. Kocakoc, A. Kaya, et al., Familial Mediterranean fever responds well to infliximab: single case experience, Clin. Rheumatol. 25 (2006) 83-87.
124. A. Mor, M.H. Pillinger, M. Kishimoto, A.M. Abeles, A. Livneh, Familial Mediterranean fever successfully treated with etanercept, Journal of clinical rheumatology: practical reports on rheumatic & musculoskeletal diseases 13 (2007) 38-40.
125. N.M. Lindor, T.M. Arsenault, H. Solomon, C.E. Seidman, M.T. McEvoy, A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome, Mayo Clin. Proc. 72 (1997) 611-615.
126. C.A. Wise, L.B. Bennett, V. Pascual, J.D. Gillum, A.M. Bowcock, Localization of a gene for familial recurrent arthritis, Arthritis Rheum. 43 (2000) 2041-2045.
127. N.G. Shoham, M. Centola, E. Mansfield, K.M. Hull, G. Wood, et al., Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway, Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 13501-13506.
128. J.W. Yu, J. Wu, Z. Zhang, P. Datta, I. Ibrahimi, et al., Cryopyrin and pyrin activate caspase-1, but not NF-kappaB, via ASC oligomerization, Cell Death Differ. 13 (2006) 236-249.
129. H.B. Yeon, N.M. Lindor, J.G. Seidman, C.E. Seidman, Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome maps to chromosome 15q, Am. J. Hum. Genet. 66 (2000) 1443-1448.
130. M.P. Dierselhuis, J. Frenkel, N.M. Wulffraat, J.J. Boelens, Anakinra for flares of pyogenic arthritis in PAPA syndrome, Rheumatology (Oxford) 44 (2005) 406-408.
131. M. Brenner, T. Ruzicka, G. Plewig, P. Thomas, P. Herzer, Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra, Br. J. Dermatol. 161 (2009) 1199-1201.
132. D.S. Stichweh, M. Punaro, V. Pascual, Dramatic improvement of pyoderma gangrenosum with infliximab in a patient with PAPA syndrome, Pediatr. Dermatol. 22 (2005) 262-265.
133. N.D. Tofteland, T.S. Shaver, Clinical efficacy of etanercept for treatment of PAPA syndrome, J. Clin. Rheumatol. 16 (2010) 244-245.
134. A.P. Demidowich, A.F. Freeman, D.B. Kuhns, I. Aksentijevich, J.I. Gallin, et al., Brief report: genotype, phenotype, and clinical course in five patients with PAPA syndrome (pyogenic sterile arthritis, pyoderma gangrenosum, and acne), Arthritis Rheum. 64 (2012) 2022-2027.
135. Z.S. Al-Mosawi, K.K. Al-Saad, R. Ijadi-Maghsoodi, H.I. El-Shanti, P.J. Ferguson, A splice site mutation confirms the role of LPIN2 in Majeed syndrome, Arthritis Rheum. 56 (2007) 960-964.
136. P.J. Ferguson, M. Sandu, Current understanding of the pathogenesis and management of chronic recurrent multifocal osteomyelitis, Curr. Rheumatol. Rep. 14 (2012) 130-141.
137. M. Colina, C. Pizzirani, M. Khodeir, S. Falzoni, M. Bruschi, et al., Dysregulation of P2X7 receptor-inflammasome axis in SAPHO syndrome: successful treatment with anakinra, Rheumatology 49 (2010) 1416-1418.
138. D. Eleftheriou, T. Gerschman, N. Sebire, P. Woo, C.A. Pilkington, et al., Biologic therapy in refractory chronic non-bacterial osteomyelitis of childhood, Rheumatology 49 (2010) 1505-1512.
139. J. Rech, B. Manger, B. Lang, G. Schett, M. Wilhelm, et al., Adult-onset Still's disease and chronic recurrent multifocal osteomyelitis: a hitherto undescribed manifestation of autoinflammation, Rheumatol. Int. 32 (2012) 1827-1829.
140. T. Herlin, M. Bjerre, B. Fiirgaard, G. Kerndrup, H. Hasle, et al., Novel mutation of the LPIN2 gene in Majeed syndrome. Response to IL-1 inhibition, Arthritis Rheum. 63 (2011) S112.
141. S.H. Mandey, L.M. Kuijk, J. Frenkel, H.R. Waterham, A role for geranylgeranylation in interleukin-1beta secretion, Arthritis Rheum. 54 (2006) 3690-3695.
142. L.M. Kuijk, S.H. Mandey, I. Schellens, H.R. Waterham, G.T. Rijkers, et al., Statin synergizes with LPS to induce IL-1beta release by THP-1 cells through activation of caspase-1, Mol. Immunol. 45 (2008) 2158-2165.
143. A. Pontillo, E. Paoluzzi, S. Crovella, The inhibition of mevalonate pathway induces upregulation of NALP3 expression: new insight in the pathogenesis of mevalonate kinase deficiency, European journal of human genetics: EJHG 18 (2010) 844-847.
144. J.C. van der Hilst, E.J. Bodar, K.S. Barron, J. Frenkel, J.P. Drenth, et al., Long-termfollow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome, Medicine (Baltimore) 87 (2008) 301-310.
145. P.D. Arkwright, M.F. McDermott, S.M. Houten, J. Frenkel, H.R. Waterham, et al., Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept, Clin. Exp. Immunol. 130 (2002) 484-488.
146. K. Takada, I. Aksentijevich, V. Mahadevan, J.A. Dean, R.I. Kelley, et al., Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome, Arthritis Rheum. 48 (2003) 2645-2651.
147. F. Marchetti, E. Barbi, A. Tommasini, C. Oretti, A. Ventura, Inefficacy of etanercept in a child with hyper-IgD syndrome and periodic fever, Clin. Exp. Rheumatol. 22 (2004) 791-792.
148. R. Topaloglu, N.A. Ayaz, H.R. Waterham, A. Yuce, F. Gumruk, et al., Hyperimmunoglobulinemia D and periodic fever syndrome; treatment with etanercept and follow-up, Clin. Rheumatol. 27 (2008) 1317-1320.
149. H.M. Shendi, D.Walsh, J.D. Edgar, Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndrome, Rheumatol. Int. 32 (2012) 249-251.
150. M. Cailliez, F. Garaix, C. Rousset-Rouviere, D. Bruno, I. Kone-Paut, et al., Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis, J. Inherit. Metab. Dis. 29 (2006) 763.
151. D. Rigante, V. Ansuini, B. Bertoni, A.L. Pugliese, L. Avallone, et al., Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome, Rheumatol. Int. 27 (2006) 97-100.
152. M. Stenerson, K. Dufendach, I. Aksentijevich, J. Brady, J. Austin, et al., The first reported case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1 receptor antagonist, Arthritis Rheum. 63 (2011) 4018-4022.
153. P.G. Thacker, L.A. Binkovitz, K.B. Thomas, Deficiency of interleukin-1-receptor antagonist syndrome: a rare auto-inflammatory condition that mimics multiple classic radiographic findings, Pediatr. Radiol. 42 (2012) 495-498.
154. S. Reddy, S. Jia, R. Geoffrey, R. Lorier, M. Suchi, et al., An autoinflammatory disease due to homozygous deletion of the IL1RN locus, N. Engl. J. Med. 360 (2009) 2438-2444.
155. A. Onoufriadis, M.A. Simpson, A.E. Pink, P. Di Meglio, C.H. Smith, et al., Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis, Am. J. Hum. Genet. 89 (2011) 432-437.
156. R.A. Terkeltaub, Clinical practice. Gout, N. Engl. J. Med. 349 (2003) 1647-1655.
157. D. McGonagle, A.L. Tan, J. Madden, P. Emery, M.F. McDermott, Successful treatment of resistant pseudogout with anakinra, Arthritis Rheum. 58 (2008) 631-633.
158. N. Announ, G. Palmer, P.A. Guerne, C. Gabay, Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure, Joint Bone Spine 76 (2009) 424-426.
159. Novartis media releases (2013) Novartis receives EU approval for Ilaris® in patients suffering acute gouty arthritis attacks who cannot gain relief from current treatments. http://wwwnovartiscom/newsroom/media-releases/en/2013/ 1681891shtml.
160. C. Fiehn, M. Zeier, Successful treatment of chronic tophaceous gout with infliximab (Remicade), Rheumatol. Int. 26 (2006) 274-276.
161. K. Bendtzen, T. Mandrup-Poulsen, J. Nerup, J.H. Nielsen, C.A. Dinarello, et al., Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans, Science 232 (1986) 1545-1547.
162. K. Maedler, P. Sergeev, F. Ris, J. Oberholzer, H.I. Joller-Jemelka, et al., Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets, J. Clin. Invest. 110 (2002) 851-860.
163. S.L. Masters, A. Dunne, S.L. Subramanian, R.L. Hull, G.M. Tannahill, et al., Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes, Nat. Immunol. 11 (2010) 897-904.
164. S.L. Masters, L.A. O'Neill, Disease-associated amyloid and misfolded protein aggregates activate the inflammasome, Trends Mol. Med. 17 (2011) 276-282.
165. M.Y. Donath, J. Storling, L.A. Berchtold, N. Billestrup, T. Mandrup-Poulsen, Cytokines and beta-cell biology: from concept to clinical translation, Endocr. Rev. 29 (2008) 334-350.
166. C. Cavelti-Weder, A. Babians-Brunner, C. Keller, M.A. Stahel, M. Kurz-Levin, et al., Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes, Diabetes Care 35 (2012) 1654-1662.
167. C.J. Tack, R. Stienstra, L.A. Joosten, M.G. Netea, Inflammation links excess fat to insulin resistance: the role of the interleukin-1 family, Immunol. Rev. 249 (2012) 239-252.
168. J.C. Randle, M.W. Harding, G. Ku, M. Schonharting, R. Kurrle, ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs, Expert Opin. Investig. Drugs 10 (2001) 1207-1209.
169. J. Loock, P. Lamprecht, C. Timmann, U. Mrowietz, E. Csernok, et al., Genetic predisposition (NLRP3 V198M mutation) for IL-1-mediated inflammation in a patient with Schnitzler syndrome, J. Allergy Clin. Immunol. 125 (2010) 500-502.
170. G. Porksen, P. Lohse, A. Rosen-Wolff, S. Heyden, T. Forster, et al., Periodic fever, mild arthralgias, and reversiblemoderate and severe organ inflammation associated with the V198M mutation in the CIAS1 gene in three German patients- expanding phenotype of CIAS1 related autoinflammatory syndrome, Eur. J. Haematol. 73 (2004) 123-127.
171. D. Lipsker, The Schnitzler syndrome, Orphanet J. Rare Dis. 5 (2010) 38.
172. H.D. de Koning, E.J. Bodar, J.W. van der Meer, A. Simon, Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment, Semin. Arthritis Rheum. 37 (2007) 137-148.
173. D. Lipsker, Y. Veran, F. Grunenberger, B. Cribier, E. Heid, et al., The Schnitzler syndrome. Four new cases and review of the literature, Medicine 80 (2001) 37-44.
174. T. Volz, F. Wolbing, J. Fischer, M. Braun, I. Maggoschitz, et al., Dermal interleukin-1 expression and effective and long-lasting therapy with interleukin-1 receptor antagonist anakinra in Schnitzler syndrome, Acta Derm. Venereol. 92 (2012) 393-394.
175. M. Gilson, S. Abad, C. Larroche, R. Dhote, Treatment of Schnitzler's syndrome with anakinra, Clin. Exp. Rheumatol. 25 (2007) 931.
176. S.W. Schneider, M. Gaubitz, T.A. Luger, G. Bonsmann, Prompt response of refractory Schnitzler syndrome to treatment with anakinra, J. Am. Acad. Dermatol. 56 (2007) S120-S122.
177. L.A. Devlin, G. Wright, J.D. Edgar, A rare cause of a common symptom, Anakinra is effective in the urticaria of Schnitzler Syndrome: a case report, Cases J 1 (2008) 348.
178. F. Dybowski, N. Sepp, H.J. Bergerhausen, J. Braun, Successful use of anakinra to treat refractory Schnitzler's syndrome, Clin. Exp. Rheumatol. 26 (2008) 354-357.
179. E. Eiling, M. Moller, I. Kreiselmaier, J. Brasch, T. Schwarz, Schnitzler syndrome: treatment failure to rituximab but response to anakinra, J. Am. Acad. Dermatol. 57 (2007) 361-364.
180. P.A. Frischmeyer-Guerrerio, R. Rachamalla, S.S. Saini, Remission of Schnitzler syndrome after treatment with anakinra, Ann. Allergy Asthma Immunol. 100 (2008) 617-619.
181. H.D. de Koning, E.J. Bodar, A. Simon, J.C. van der Hilst, M.G. Netea, et al., Beneficial response to anakinra and thalidomide in Schnitzler's syndrome, Ann. Rheum. Dis. 65 (2006) 542-544.
182. V.M. Martinez-Taboada, A. Fontalba, R. Blanco, J.L. Fernandez-Luna, Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al, Arthritis Rheum. 52 (2005) 2226-2227.
183. J.G. Ryan, H.D. de Koning, L.A. Beck, M.G. Booty, D.L. Kastner, et al., IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission, J. Allergy Clin. Immunol. 121 (2008) 260-262.
184. N. Kanazawa, I. Okafuji, N. Kambe, R. Nishikomori, M. Nakata-Hizume, et al., Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome, Blood 105 (2005) 1195-1197.
185. E.B. Blau, Familial granulomatous arthritis, iritis, and rash, J. Pediatr. 107 (1985) 689-693.
186. D.A. Jabs, J.L. Houk, W.B. Bias, F.C. Arnett, Familial granulomatous synovitis, uveitis, and cranial neuropathies, Am. J. Med. 78 (1985) 801-804.
187. J.I. Arostegui, C. Arnal, R. Merino, C. Modesto, M. Antonia Carballo, et al., NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvementwith interleukin-1 blockade in a Spanish cohort, Arthritis Rheum. 56 (2007) 3805-3813.
188. K. Yasui, M. Yashiro, M. Tsuge, A. Manki, K. Takemoto, et al., Thalidomide dramatically improves the symptoms of earlyonset sarcoidosis/Blau syndrome: its possible action and mechanism, Arthritis Rheum. 62 (2010) 250-257.
189. R. Caorsi, S. Federici, M. Gattorno, Biologic drugs in autoinflammatory syndromes, Autoimmun. Rev. (2012).
190. A.C. Brescia, G. McIlvain-Sompson, C.D. Rose, Infliximab therapy for steroid-dependent early onset sarcoid arthritis and Blau syndrome [abstract], Arthritis Rheum. 46 (2002) S313.
191. C.D. Rose, C.H. Wouters, S. Meiorin, T.M. Doyle, M.P. Davey, et al., Pediatric granulomatous arthritis: an international registry, Arthritis Rheum. 54 (2006) 3337-3344.
192. T.M. Martin, Z. Zhang, P. Kurz, C.D. Rose, H. Chen, et al., The NOD2 defect in Blau syndrome does not result in excess interleukin-1 activity, Arthritis Rheum. 60 (2009) 611-618.
193. I. Jeru, P. Duquesnoy, T. Fernandes-Alnemri, E. Cochet, J.W. Yu, et al., Mutations in NALP12 cause hereditary periodic fever syndromes, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 1614-1619.
194. S. Borghini, S. Tassi, S. Chiesa, F. Caroli, S. Carta, et al., Clinical presentation and pathogenesis of cold-induced autoinflammatory disease in a family with recurrence of an NLRP12 mutation, Arthritis Rheum. 63 (2011) 830-839.
195. I. Jeru, V. Hentgen, S. Normand, P. Duquesnoy, E. Cochet, et al., Role of interleukin-1beta in NLRP12-associated autoinflammatory disorders and resistance to anti-interleukin-1 therapy, Arthritis Rheum. 63 (2011) 2142-2148.
196. S. Savic, L.J. Dickie, M. Battellino, M.F. McDermott, Familial Mediterranean fever and related periodic fever syndromes/ autoinflammatory diseases, Curr. Opin. Rheumatol. 24 (2012) 103-112.
197. E. Aganna, L. Hammond, P.N. Hawkins, A. Aldea, S.A. McKee, et al., Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes, Arthritis Rheum. 48 (2003) 2632-2644.
198. M.L. Huggins, P.M. Radford, R.S. McIntosh, S.E. Bainbridge, P. Dickinson, et al., Shedding of mutant tumor necrosis factor receptor superfamily 1A associated with tumor necrosis factor receptor-associated periodic syndrome: differences between cell types, Arthritis Rheum. 50 (2004) 2651-2659.
199. A. D'Osualdo, F. Ferlito, I. Prigione, L. Obici, A. Meini, et al., Neutrophils from patients with TNFRSF1A mutations display resistance to tumor necrosis factor-induced apoptosis: pathogenetic and clinical implications, Arthritis Rheum. 54 (2006) 998-1008.
200. S.L. Rebelo, S.E. Bainbridge, M.R. Amel-Kashipaz, P.M. Radford, R.J. Powell, et al., Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function, Arthritis Rheum. 54 (2006) 2674-2687.
201. A. Simon, H. Park, R. Maddipati, A.A. Lobito, A.C. Bulua, et al., Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome, Proc. Natl. Acad. Sci. U. S. A. 107 (2010) 9801-9806.
202. A.C. Bulua, A. Simon, R. Maddipati, M. Pelletier, H. Park, et al., Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS), J. Exp. Med. 208 (2011) 519-533.
203. K.M. Hull, I. Aksentijevich, H.K. Singh, Efficacy of etanercept for the treatment of patients with TNF receptor-associated periodic syndrome (TRAPS), Arthritis Rheum. 46 (2002) S378.
204. E. Drewe, E.M. McDermott, P.T. Powell, J.D. Isaacs, R.J. Powell, Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients, Rheumatology 42 (2003) 235-239.
205. S. Jacobelli, M. Andre, J.F. Alexandra, C. Dode, T. Papo, Failure of anti-TNF therapy in TNF Receptor 1-Associated Periodic Syndrome (TRAPS), Rheumatology (Oxford) 46 (2007) 1211-1212.
206. A.C. Bulua, D.B. Mogul, I. Aksentijevich, H. Singh, D.Y. He, et al., Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study, Arthritis Rheum. 64 (2012) 908-913.
207. B. Nedjai, G.A. Hitman, N. Quillinan, R.J. Coughlan, L. Church, et al., Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome, Arthritis Rheum. 60 (2009) 619-625.
208. S. Gudbrandsdottir, R. Larsen, L.K. Sorensen, S. Nielsen, M.B. Hansen, et al., TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis, Clin. Exp. Rheumatol. 22 (2004) 118-124.
209. C.A. Dinarello, J.G. Cannon, S.M. Wolff, H.A. Bernheim, B. Beutler, et al., Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1, J. Exp. Med. 163 (1986) 1433-1450.
210. M. Gattorno, M.A. Pelagatti, A. Meini, L. Obici, R. Barcellona, et al., Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome, Arthritis Rheum. 58 (2008) 1516-1520.
211. K. Sacre, B. Brihaye, O. Lidove, T. Papo, M.A. Pocidalo, et al., Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy, J. Rheumatol. 35 (2008) 357-358.
212. A. Simon, E.J. Bodar, J.C. van der Hilst, J.W. van der Meer, T.J. Fiselier, et al., Beneficial response to interleukin 1 receptor antagonist in traps, Am. J. Med. 117 (2004) 208-210.
213. P.M. Vaitla, P.M. Radford, P.J. Tighe, R.J. Powell, E.M. McDermott, et al., Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab, Arthritis Rheum. 63 (2011) 1151-1155.
214. M. Gattorno, L. Obici, A. Meini, V. Tormey, K. Abrams, et al., Efficacy and safety of canakinumab in patients with TNF receptor associated periodic syndrome (TRAPS), Ann. Rheum. Dis. 71 (2012) 289.
215. P. Bowness, HLA B27 in health and disease: a double-edged sword? Rheumatology 41 (2002) 857-868.
216. J. Braun, J. Sieper, Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches, Arthritis Res. 4 (2002) 307-321.
217. C. Ambarus, N. Yeremenko, P.P. Tak, D. Baeten, Pathogenesis of spondyloarthritis: autoimmune or autoinflammatory? Curr. Opin. Rheumatol. 24 (2012) 351-358.
218. R. Singh, A. Aggarwal, R. Misra, Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy, J. Rheumatol. 34 (2007) 2285-2290.
219. I. Garcia-Valladares, R. Cuchacovich, L.R. Espinoza, Psoriatic arthritis: radiographic joint repair following etanercept therapy, J. Rheumatol. 39 (2012) 185, author reply 186.
220. C. Palazzi, S. D'Angelo, F. Cantini, E. Lubrano, A. Marchesoni, et al., Etanercept in spondyloarthropathies. Part I: current evidence of efficacy, Clin. Exp. Rheumatol. 29 (2011) 858-864.
221. P. Mease, M.C. Genovese, G. Gladstein, A.J. Kivitz, C. Ritchlin, et al., Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial, Arthritis Rheum. 63 (2011) 939-948.
222. G. Nocturne, M. Dougados, A. Constantin, C. Richez, J. Sellam, et al., Rituximab in the spondyloarthropathies: data of eight patients followed up in the French Autoimmunity and Rituximab (AIR) registry, Ann. Rheum. Dis. 69 (2010) 471-472.
223. I.H. Song, F. Heldmann, M. Rudwaleit, H. Haibel, A. Weiss, et al., Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study, Ann. Rheum. Dis. 70 (2011) 1108-1110.
224. I.H. Song, F. Heldmann, M. Rudwaleit, J. Listing, H. Appel, et al., Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial, Arthritis Rheum. 62 (2010) 1290-1297.
225. I.H. Song, F. Heldmann, M. Rudwaleit, J. Listing, H. Appel, et al., One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare, Ann. Rheum. Dis. (2012).
226. K.A. Papp, Monitoring patients treated with efalizumab or alefacept, Curr. Probl. Dermatol. 38 (2009) 95-106.
227. V. Pascual, F. Allantaz, E. Arce, M. Punaro, J. Banchereau, Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade, J. Exp. Med. 201 (2005) 1479-1486.
228. J.W. Verbsky, A.J. White, Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis, J. Rheumatol. 31 (2004) 2071-2075.
229. V. Ohlsson, E. Baildam, H. Foster, S. Jandial, C. Pain, et al., Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA), Rheumatology 47 (2008) 555-556.
230. M. Gattorno, A. Piccini, D. Lasiglie, S. Tassi, G. Brisca, et al., The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis, Arthritis Rheum. 58 (2008) 1505-1515.
231. A. Zeft, R. Hollister, B. LaFleur, P. Sampath, J. Soep, et al., Anakinra for systemic juvenile arthritis: the Rocky Mountain experience, Journal of clinical rheumatology: practical reports on rheumatic & musculoskeletal diseases 15 (2009) 161-164.
232. P. Quartier, F. Allantaz, R. Cimaz, P. Pillet, C. Messiaen, et al., A multicentre, randomised, double-blind, placebocontrolled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial), Ann. Rheum. Dis. 70 (2011) 747-754.
233. P.A. Nigrovic, M. Mannion, F.H. Prince, A. Zeft, C.E. Rabinovich, et al., Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series, Arthritis Rheum. 63 (2011) 545-555.
234. F. de Benedetti, M. Massa, P. Robbioni, A. Ravelli, G.R. Burgio, et al., Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis, Arthritis Rheum. 34 (1991) 1158-1163.
235. S. Yokota, T. Miyamae, T. Imagawa, N. Iwata, S. Katakura, et al., Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis, Arthritis Rheum. 52 (2005) 818-825.
236. F. De Benedetti, H. Brunner, N. Ruperto, A. Kenwright, C. Devlin, et al., Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): 2-year data from TENDER, a phase 3 clinical trial, Ann. Rheum. Dis. 71 (2012) 425.
237. G. Horneff, H. Schmeling, T. Biedermann, I. Foeldvari, G. Ganser, et al., The German etanercept registry for treatment of juvenile idiopathic arthritis, Ann. Rheum. Dis. 63 (2004) 1638-1644.
238. A. Reiff, The use of anakinra in juvenile arthritis, Curr. Rheumatol. Rep. 7 (2005) 434-440.
239. D.Y. Chen, J.L. Lan, F.J. Lin, T.Y. Hsieh, M.C. Wen, Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still's disease, Ann. Rheum. Dis. 63 (2004) 1300-1306.
240. D.Y. Chen, Y.M. Chen, J.L. Lan, C.C. Lin, H.H. Chen, et al., Potential role of Th17 cells in the pathogenesis of adult-onset Still's disease, Rheumatology 49 (2010) 2305-2312.
241. M.E. Husni, A.L. Maier, P.J. Mease, S.S. Overman, P. Fraser, et al., Etanercept in the treatment of adult patients with Still's disease, Arthritis Rheum. 46 (2002) 1171-1176.
242. B. Fautrel, J. Sibilia, X. Mariette, B. Combe, Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases, Ann. Rheum. Dis. 64 (2005) 262-266.
243. H.G. Kraetsch, C. Antoni, J.R. Kalden, B. Manger, Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences, Ann. Rheum. Dis. 60 (Suppl. 3) (2001) iii55-iii57.
244. C. Dechant, P. Schauenberg, C.E. Antoni, H.G. Kraetsch, J.R. Kalden, et al., Longterm outcome of TNF blockade in adult-onset Still's disease, Deutsche medizinische Wochenschrift 129 (2004) 1308-1312.
245. A. Kokkinos, A. Iliopoulos, P. Greka, A. Efthymiou, N. Katsilambros, et al., Successful treatment of refractory adultonset Still's disease with infliximab. A prospective, noncomparative series of four patients, Clin. Rheumatol. 23 (2004) 45-49.
246. A.A. Fitzgerald, S.A. Leclercq, A. Yan, J.E. Homik, C.A. Dinarello, Rapid responses to anakinra in patients with refractory adult-onset Still's disease, Arthritis Rheum. 52 (2005) 1794-1803.
247. I. Kotter, A. Wacker, S. Koch, J. Henes, C. Richter, et al., Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature, Semin. Arthritis Rheum. 37 (2007) 189-197.
248. G.D. Kalliolias, P.E. Georgiou, I.A. Antonopoulos, A.P. Andonopoulos, S.N. Liossis, Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial, Ann. Rheum. Dis. 66 (2007) 842-843.
249. K. Laskari, A.G. Tzioufas, H.M. Moutsopoulos, Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study, Arthritis Res. Ther. 13 (2011) R91.
250. D. Nordstrom, A. Knight, R. Luukkainen, R. van Vollenhoven, V. Rantalaiho, et al., Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease. An open, randomized, multicenter study, J. Rheumatol. 39 (2012) 2008-2011.
251. H.J. Lachmann, P. Quartier, A. So, P.N. Hawkins, The emerging role of interleukin-1beta in autoinflammatory diseases, Arthritis Rheum. 63 (2011) 314-324.
252. O. Petryna, J.J. Cush, P. Efthimiou, IL-1 Trap rilonacept in refractory adult onset Still's disease, Ann. Rheum. Dis. 71 (2012) 2056-2057.
253. A. Kontzias, P. Efthimiou, The Use of Canakinumab, a Novel IL-1beta Long-Acting Inhibitor, in Refractory Adult-Onset Still's Disease, Semin. Arthritis Rheum. 42 (2012) 201-205.
254. F. Kaneko, A. Togashi, S. Saito, H. Sakuma, N. Oyama, et al., Behcet's disease (Adamantiades-Behcet's disease), Clin. Dev. Immunol. (2011) 681956.
255. C. Mendoza-Pinto, M. Garcia-Carrasco, M. Jimenez-Hernandez, C. Jimenez Hernandez, C. Riebeling-Navarro, et al., Etiopathogenesis of Behcet's disease, Autoimmun. Rev. 9 (2010) 241-245.
256. V.D. Kapsimali, M.A. Kanakis, G.A. Vaiopoulos, P.G. Kaklamanis, Etiopathogenesis of Behcet's disease with emphasis on the role of immunological aberrations, Clin. Rheumatol. 29 (2010) 1211-1216.
257. K.T. Thomas, H.M. Feder Jr., A.R. Lawton, K.M. Edwards, Periodic fever syndrome in children, J. Pediatr. 135 (1999) 15-21.
258. S. Stojanov, F. Hoffmann, A. Kery, E.D. Renner, D. Hartl, et al., Cytokine profile in PFAPA syndrome suggests continuous inflammation and reduced anti-inflammatory response, Eur. Cytokine Netw. 17 (2006) 90-97.
259. S. Stojanov, S. Lapidus, P. Chitkara, H. Feder, J.C. Salazar, et al., Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade, Proc. Natl. Acad. Sci. U. S. A. 108 (2011) 7148-7153.
260. L. Cantarini, A. Vitale, M. Galeazzi, B. Frediani, A case of resistant adult-onset periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis (PFAPA) syndrome responsive to anakinra, Clin. Exp. Rheumatol. 30 (2012) 593.
261. Y. Liu, Y. Ramot, A. Torrelo, A.S. Paller, N. Si, et al., Mutations in proteasome subunit beta type 8 cause chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature with evidence of genetic and phenotypic heterogeneity, Arthritis Rheum. 64 (2012) 895-907.
262. M.J. Ombrello, D.L. Kastner, Autoinflammation in 2010: expanding clinical spectrum and broadening therapeutic horizons, Nat. Rev. Rheumatol. 7 (2011) 82-84.
263. K. Bodin, S. Ellmerich, M.C. Kahan, G.A. Tennent, A. Loesch, et al., Antibodies to human serum amyloid P component eliminate visceral amyloid deposits, Nature 468 (2010) 93-97.
264. L. Kaly, I. Rosner, Tocilizumab - a novel therapy for non-organ-specific autoimmune diseases, Best Pract. Res. Clin. Rheumatol. 26 (2012) 157-165.
265. E. Ben-Chetrit, M. Levy, Colchicine: 1998 update, Semin. Arthritis Rheum. 28 (1998) 48-59.
266. L.K. Stamp, P.T. Chapman, Gout and its comorbidities: implications for therapy, Rheumatology 52 (2013) 34-44.
267. G. Cocco, D.C. Chu, S. Pandolfi, Colchicine in clinical medicine. A guide for internists, Eur. J. Intern. Med. 21 (2010) 503-508.
268. C.A. Dinarello, S.M. Wolff, S.E. Goldfinger, D.C. Dale, D.W. Alling, Colchicine therapy for familial mediterranean fever. A double-blind trial, N. Engl. J. Med. 291 (1974) 934-937.
269. D. Zemer, A. Livneh, Y.L. Danon, M. Pras, E. Sohar, Long-term colchicine treatment in children with familial Mediterranean fever, Arthritis Rheum. 34 (1991) 973-977.
270. Y. Molad, Update on colchicine and its mechanism of action, Curr. Rheumatol. Rep. 4 (2002) 252-256.
271. L. Gurcel, L. Abrami, S. Girardin, J. Tschopp, F.G. van der Goot, Caspase-1 activation of lipid metabolic pathways in response to bacterial pore-forming toxins promotes cell survival, Cell 126 (2006) 1135-1145.
272. R.R. Craven, X. Gao, I.C. Allen, D. Gris, J. Bubeck Wardenburg, et al., Staphylococcus aureus alpha-hemolysin activates the NLRP3-inflammasome in human and mouse monocytic cells, PLoS One 4 (2009) e7446.
273. R. Allam, M.N. Darisipudi, K.V. Rupanagudi, J. Lichtnekert, J. Tschopp, et al., Cutting edge: cyclic polypeptide and aminoglycoside antibiotics trigger IL-1beta secretion by activating the NLRP3 inflammasome, J. Immunol. 186 (2011) 2714-2718.
274. J. Zhou, J.Wu, X. Chen, N. Fortenbery, E. Eksioglu, et al., Icariin and its derivative, ICT, exert anti-inflammatory, anti-tumor effects, and modulate myeloid derived suppressive cells (MDSCs) functions, Int. Immunopharmacol. 11 (2011) 890-898.
275. L. Franchi, T.D. Kanneganti, G.R. Dubyak, G. Nunez, Differential requirement of P2X7 receptor and intracellular K+ for caspase-1 activation induced by intracellular and extracellular bacteria, J. Biol. Chem. 282 (2007) 18810-18818.
276. Y. Qu, L. Franchi, G. Nunez, G.R. Dubyak, Nonclassical IL-1 beta secretion stimulated by P2X7 receptors is dependent on inflammasome activation and correlated with exosome release in murine macrophages, J. Immunol. 179 (2007) 1913-1925.
277. F. Bauernfeind, E. Bartok, A. Rieger, L. Franchi, G. Nunez, et al., Cutting edge: reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome, J. Immunol. 187 (2011) 613-617.
278. A. Mayor, F. Martinon, T. De Smedt, V. Petrilli, J. Tschopp, A crucial function of SGT1 and HSP90 in inflammasome activity links mammalian and plant innate immune responses, Nat. Immunol. 8 (2007) 497-503.
279. S.J. Lalor, L.S. Dungan, C.E. Sutton, S.A. Basdeo, J.M. Fletcher, et al., Caspase-1-processed cytokines IL-1beta and IL-18 promote IL-17 production by gammadelta and CD4 T cells that mediate autoimmunity, J. Immunol. 186 (2011) 5738-5748.
280. S. Cornelis, K. Kersse, N. Festjens, M. Lamkanfi, P. Vandenabeele, Inflammatory caspases: targets for novel therapies, Curr. Pharm. Des. 13 (2007) 367-385.
281. J.H. Stack, K. Beaumont, P.D. Larsen, K.S. Straley, G.W. Henkel, et al., IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients, J. Immunol. 175 (2005) 2630-2634.
282. A.M. Owyang, K. Maedler, L. Gross, J. Yin, L. Esposito, et al., XOMA 052, an anti-IL-1{beta} monoclonal antibody, improves glucose control and {beta}-cell function in the diet-induced obesity mouse model, Endocrinology 151 (2010) 2515-2527.
283. A. Kontzias, A. Kotlyar, A. Laurence, P. Changelian, J.J. O'Shea, Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease, Curr. Opin. Pharmacol. 12 (2012) 464-470.
284. A. Laurence, M. Pesu, O. Silvennoinen, J. O'Shea, JAK Kinases in Health and Disease: An Update, The open rheumatology journal 6 (2012) 232-244.
285. H.M. Hoffman, M.L. Throne, N.J. Amar, R.C. Cartwright, A.J. Kivitz, et al., Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study, Clin. Ther. 34 (2012) 2091-2103.
286. J.B. Kuemmerle-Deschner, E. Ramos, N. Blank, J. Roesler, S.D. Felix, et al., Canakinumab (ACZ885, a fully human IgG1 anti-IL-1beta mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS), Arthritis Res. Ther. 13 (2011) R34.
287. S. Ozen, Y. Bilginer, N. Aktay Ayaz, M. Calguneri, Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine, J. Rheumatol. 38 (2011) 516-518.
288. P.J. Hashkes, S.J. Spalding, E.H. Giannini, B. Huang, A. Johnson, et al., Rilonacept for colchicine-resistant or -intolerant familial Mediterranean fever: a randomized trial, Ann. Intern. Med. 157 (2012) 533-541.
289. O. Akgul, E. Kilic, G. Kilic, S. Ozgocmen, Efficacy and Safety of Biologic Treatments in Familial Mediterranean Fever, Am. J. Med. Sci. (2012), Epub ahead of print.
290. B. Bader-Meunier, B. Florkin, J. Sibilia, C. Acquaviva, E. Hachulla, et al., Mevalonate kinase deficiency: a survey of 50 patients, Pediatrics 128 (2011) e152-e159.
291. A. Molto, H.K. Ea, P. Richette, T. Bardin, F. Liote, Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis, Joint, bone, spine: revue du rhumatisme 79 (2012) 621-623.
292. H.R. Schumacher Jr., J.S. Sundy, R. Terkeltaub, H.R. Knapp, S.J. Mellis, et al., Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebocontrolled trial, Arthritis Rheum. 64 (2012) 876-884.
293. H.R. Schumacher Jr., R.R. Evans, K.G. Saag, J. Clower, W. Jennings, et al., Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study, Arthritis Care Res. 64 (2012) 1462-1470.
294. E. Mitha, H.R. Schumacher, L. Fouche, S.F. Luo, S.P. Weinstein, et al., Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial, Rheumatology (2013), Epub ahead of print.
295. N. Schlesinger, R.E. Alten, T. Bardin, H.R. Schumacher, M. Bloch, et al., Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions, Ann. Rheum. Dis. 71 (2012) 1839-1848.
296. A. Simon, B. Asli, M. Braun-Falco, H. De Koning, J.P. Fermand, et al., Schnitzler's syndrome: diagnosis, treatment, and follow-up, Allergy 68 (2013) 562-568.
297. N. Pazyar, A. Feily, R. Yaghoobi, An overview of interleukin-1 receptor antagonist, anakinra, in the treatment of cutaneous diseases, Curr. Clin. Pharmacol. 7 (2012) 271-275.
298. G. Simonini, Z. Xu, R. Caputo, C. De Libero, I. Pagnini, et al., Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis, Arthritis Rheum. 65 (2013) 513-518.
299. N. Quillinan, G. Mannion, A. Mohammad, R. Coughlan, L.J. Dickie, et al., Failure of sustained response to etanercept and refractoriness to anakinra in patients with T50M TNF-receptorassociated periodic syndrome, Ann. Rheum. Dis. 70 (2011) 1692-1693.
300. E. Drewe, M.L. Huggins, A.G. Morgan, M.J. Cassidy, R.J. Powell, Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome, Rheumatology (Oxford) 43 (2004) 1405-1408.
301. J.I. Arostegui, P. Solis, A. Aldea, T. Cantero, J. Rius, et al., Etanercept plus colchicine treatment in a child with tumour necrosis factor receptor-associated periodic syndrome abolishes auto-inflammatory episodes without normalising the subclinical acute phase response, Eur. J. Pediatr. 164 (2005) 13-16.
302. A.A. Jesus, J.B. Oliveira, I. Aksentijevich, E. Fujihira, M.M. Carneiro-Sampaio, et al., TNF receptor-associated periodic syndrome (TRAPS): description of a novel TNFRSF1A mutation and response to etanercept, Eur. J. Pediatr. 167 (2008) 1421-1425.
303. E. Drewe, R.J. Powell, E.M. McDermott, Comment on: Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS), Rheumatology 46 (2007) 1865-1866.
304. M. Dougados, J. Braun, S. Szanto, B. Combe, P. Geher, et al., Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study, Rheumatology 51 (2012) 1687-1696.
305. I.H. Song, C.E. Althoff, H. Haibel, K.G. Hermann, D. Poddubnyy, et al., Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial, Ann. Rheum. Dis. 71 (2012) 1212-1215.
306. J. Braun, X. Baraliakos, J. Brandt, J. Listing, A. Zink, et al., Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years, Rheumatology 44 (2005) 670-676.
307. X. Baraliakos, J. Listing, C. Fritz, H. Haibel, R. Alten, et al., Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years-early clinical response predicts long-term outcome, Rheumatology 50 (2011) 1690-1699.
308. G. Horneff, S. Fitter, I. Foeldvari, K. Minden, J. Kuemmerle-Deschner, et al., Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement, Arthritis Res. Ther. 14 (2012) R230.
309. D. Wendling, M. Dougados, F. Berenbaum, O. Brocq, T. Schaeverbeke, et al., Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology, J. Rheumatol. 39 (2012) 2327-2331.
310. M. Gattorno, A. Naselli, A. Accogli, S. Chiesa, R. Caorsi, et al., Long-term follow-up of systemic onset juvenile idiopathic arthritis patients treated with anakinra, Pediatric rheumatology online journal 9 (2011) P158.
311. D.J. Lovell, E.H. Giannini, Y.L. Kimura, C. Suzanne, P.J. Hashkes, et al., Long-term safety and efficacy of rilonacept in patients with systemic juvenile idiopathic arthritis (SJIA) [abstract], Arthritis Rheum. 60 (2009) 2053.
312. N. Ruperto, H.I. Brunner, P. Quartier, T. Constantin, N. Wulffraat, et al., Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis, N. Engl. J. Med. 367 (2012) 2396-2406.
313. C. Giampietro, M. Ridene, T. Lequerre, N. Costedoat Chalumeau, Z. Amoura, et al., Anakinra in Adult-Onset Still's Disease: Long-Term Treatment in Patients Resistant to Conventional Therapy, Arthritis Care Res. 65 (2013) 822-826.
314. H. de Boysson, J. Fevrier, A. Nicolle, C. Auzary, L. Geffray, Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence, Clin. Rheumatol. 32 (2013) 141-147.
315. V. Curigliano, M. Giovinale, C. Fonnesu, C. Cerquaglia, E. Verrecchia, et al., Efficacy of etanercept in the treatment of a patient with Behcet's disease, Clin. Rheumatol. 27 (2008) 933-936.
316. M.F. Zhang, C. Zhao, X. Wen, H. Du, Y. Zhao, The short-term efficacy and safety treatment study of recurrent uveitis in Behcet disease with etanercept, [Zhonghua yan ke za zhi] Chinese journal of ophthalmology 46 (2010) 145-150.
317. S. Iwata, K. Saito, K. Yamaoka, S. Tsujimura, M. Nawata, et al., Efficacy of combination therapy of anti-TNF-alpha antibody infliximab and methotrexate in refractory entero-Behcet's disease, Modern rheumatology / the Japan Rheumatism Association 21 (2011) 184-191.
318. A. Borhani Haghighi, A. Safari, M.A. Nazarinia, Z. Habibagahi, S. Shenavandeh, Infliximab for patients with neuro-Behcet's disease: case series and literature review, Clin. Rheumatol. 30 (2011) 1007-1012.
319. N. Markomichelakis, E. Delicha, S. Masselos, K. Fragiadaki, P. Kaklamanis, et al., A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behcet's disease: a comparative 4-week study, Rheumatology 50 (2011) 593-597.